Top

Sleep and Breathing

Published in:

01-12-2017 | Sleep Breathing Physiology and Disorders • Original Article

Effects of CPAP in patients with obstructive apnoea: is the presence of allergic rhinitis relevant?

Authors: A. Cisternas, F. Aguilar, J. M. Montserrat, M. Àvila, M. Torres, A. Iranzo, J. Berenguer, I. Vilaseca

Published in: Sleep and Breathing | Issue 4/2017

Abstract

Purpose

The aim of the study is to compare the effects of continuous positive airway pressure (CPAP) on the nasal cavities of patients with obstructive sleep apnoea (OSA) and with or without allergic rhinitis (AR/nonAR).

Methods

This paper is a prospective, longitudinal study. Thirty-four consecutive CPAP treatment-adherent patients with OSA (17 AR and 17 nonAR) were evaluated before and 2 months after treatment, by means of clinical (otorhinolaryngological symptoms, daytime sleepiness, overall and rhinoconjunctivitis-specific quality of life), anatomical (otorhinolaryngological examination), functional (auditory function, tubal function, nasal airflow, and mucociliary clearance), and biological variables (nasal cytology). No humidifier or anti-allergy medicines were used during treatment.

Results

Before treatment, patients with AR presented a higher score, compared to nonAR in rhinitis symptoms (4.82 ± 2.53 vs. 0.93 ± 1.02, p = 0.000), otologic symptoms (2.06 ± 1.95 vs. 0.44 ± 0.72, p = 0.004), cutaneous/ocular symptoms (2.12 ± 2.17 vs. 0.65 ± 1.17, p = 0.052), immunoglobulin E (181.82 ± 126.09 vs. 66.13 ± 97.97, p = 0.004), and nasal neutrophils (14.42 ± 31.94 vs. 0.16 ± 0.39, p = 0.031). After treatment, nonAR and AR groups improved in daytime sleepiness (11.53 ± 4.60 vs. 7.53 ± 2.87, p = 0.000 and 13.76 ± 4.93 vs. 7.53 ± 4.41, p = 0.001) respectively and increased nasal neutrophil (0.16 ± 0.39 vs. 5.78 ± 9.43, p = 0.001 and 14.42 ± 31.94 vs. 79.47 ± 202.08, p = 0.035). The symptoms and quality of life improved in patients with AR. NonAR patients, significantly increase nasal dryness (1.65 ± 1.27 vs. 0.00, p = 0.002) and mucociliary clearance times (38.59 ± 24.90 vs. 26.82 ± 23.18, p = 0.016).

Conclusions

CPAP produces inflammation with increased nasal neutrophil levels in AR and nonAR patients. Nevertheless, patients with AR observed an improvement in nasal symptoms and quality of life, whereas in patients without AR, a relevant worsening of nasal dryness and mucociliary transport was observed.

Basner R (2007) Continuous positive airway pressure for obstructive sleep apnea. N Engl J Med 356(17):1751–1758CrossRefPubMed

Catcheside PG (2010). Preditors of continuous positive airway pressure adherence. F1000 medicine reports 2: 70.

Devouassoux G, Lévy P, Rossini E et al (2007) Sleep apnea is associated with bronchial inflammation and continuous positive airway pressure-induced airway hyperresponsiveness. J Allergy Clin Immunol 119(3):597–603CrossRefPubMed

Weaver TE, Grunstein RR (2008) Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc 5(2):173–178CrossRefPubMedPubMedCentral

Bauchau V, Durham SR (2004) Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 24:758–764CrossRefPubMed

Grupo Español de Sueño (2005). Consenso Nacional sobre el síndrome de apneas-hipopneas del sueño. Arch Bronconeumol 41: 3–110.

Vilaseca I, Lehrer-Coriat E, Torres M, Aguilar F, Almendros I, Martínez-Vidal BM, Montserrat JM (2016) Early effects of continuous positive airway pressure in a rodent model of allergic rhinitis. Sleep Med 27-28:25–27CrossRefPubMed

Lloberes P, Durán-Cantolla J, Martínez-García MA, Marín JM, Ferrer A, Corral J et al (2011) Diagnosis and treatment of sleep apnea-hypopnea syndrome. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol 47(3):143–156CrossRefPubMed

Aguilar F, Cisternas A, Montserrat JM, Ávila M, Torres-López M, Iranzo A, Berenguer J, Vilaseca I (2016) Efecto de la presión positiva continua nasal sobre las fosas nasales de pacientes con Síndrome de Apneas del Sueño sin patología nasal previa. Factores predictivos de cumplimiento. Arch Bronconeumol 52:519–526CrossRefPubMed

10.

Dreborg S, Backma A, Basomba A, Bousquet J, Dieges P, Malling HJ (1989) Skin tests used in type I allergy testing. Allergy 44:1–59CrossRef

11.

Johns MW (1993) Daytime sleepiness, snoring and obstructive sleep apnea. The Epworth Sleepniness Scale. Chest 103(1):30–36CrossRefPubMed

12.

Vilagut G, Ferrer M, Rajmil M, Rebollo P, Permanyer-Miralda G, Quintana JM et al (2005) El cuestionario de salud SF-36 español: una década de experiencia y nuevos desarrollos. Gac Sanit 19(2):135–150CrossRefPubMed

13.

Juniper EF, Thompson AK, Ferrie PJ, Roberts JN (1999) Validation of a standardised version of the rhinoconjunctivitis quality of life questionnaire. J allergy Clin Immunol 104(2pt1):364–369CrossRefPubMed

14.

Stewart MG, Witsell DI, Smith TL, Weaver EM, Yueti B, Hannley MT (2004) Development and validation of the Nasal Obstruction Symptom Evaluation (NOSE) Scale. Otolaryngology - Head and Neck Surg 130(2):157–163CrossRef

15.

Rasp G, Kramer MF, Ostertag P, Kastenbauer E (2000) A new system for the classification of ethmoid polyposis. Effect of combined local and systemic steroid therapy. Laryngorhinootologie 79(5):266–272CrossRefPubMed

16.

Rasp G (2002) Eosinophil inflammation of the nasal mucosa. Laryngorhinootologie 81(7):491–498CrossRefPubMed

17.

Fabra Llopis JM (1990) Rinomanometría anterior activa informatizada: criterios de normalidad y fiabilidad de la prueba. Doctoral Thesis. Universidad Autónoma de Barcelona, Barcelona

18.

Andersen IB, Camner P, Jensen PL, Philipson K, Proctor DF (1974) A comparison of nasal and tracheobroncuial clearance. Arch Environ Health 29(5):290–293CrossRefPubMed

19.

Portmann M, Portmann C (1979). Audiometría Clínica. Barcelona: Toray-Masson (3^rd edition).

20.

Skoczinski S, Ograbek-Król M, Tazbirek M, Semik-Orzech A, Pierzehala W (2008) Short-term CPAP treatment induces a mild increase in inflammatory cells in patients with sleep apnea syndrome. Rhinology 46(2):144–150

21.

Gelardi M, Carbonara G, Maffezzoni E, Marvisi M, Quaranta N, Ferri R (2012) Regular CPAP utilization reduces nasal inflammation assessed by nasal cytology in obstructive sleep apnea syndrome. Sleep Med 13(7):859–863CrossRefPubMed

22.

Pawankar R, Hayashi M, Yamanishi S, Igarashi T (2015) The paradigm of cytokine networks in allergic airway inflammation. Curr Opin Allergy Clin Immunol 15(1):41–48CrossRefPubMed

23.

Martinez B, Farré R, Montserrat JM, Torres M, Almendros I, Aguilar F et al (2010) Effects of heated humidification on nasal inflammation in a CPAP rat model. Sleep Med 11(4):413–416CrossRef

24.

Lacedonia D, Salerno FG, Carpagnano GE, Sabato R, Depalo A, Foschino-Barbaro MP (2011) Effects of CPAP-therapy on bronchial and nasal inflammation in patients affected of obstructive sleep apnea syndrome. Rhinology 49(2):232–237PubMed

25.

Bossi R, Piatti G, Roma E, Ambrosetti U (2004) Effects of long-term nasal continuous positive airway pressure therapy on morphology, function, and mucociliary clearance of nasal epithelium in patients with obstructive sleep apnea syndrome. Laryngoscope 114(8):1431–1434CrossRefPubMed

26.

Saka C, Vuralkan E, Fırat IH, Alicura S, Hücümenoğlu S, Akın I et al (2012) The effects of CPAP treatment on nasal mucosa in patients with obstructive sleep apnea. Eur Arch Otorhinolaryngol 269(9):2065–2067CrossRefPubMed

Title: Effects of CPAP in patients with obstructive apnoea: is the presence of allergic rhinitis relevant?
Authors: A. Cisternas
F. Aguilar
J. M. Montserrat
M. Àvila
M. Torres
A. Iranzo
J. Berenguer
I. Vilaseca
Publication date: 01-12-2017
Publisher: Springer International Publishing
Published in: Sleep and Breathing / Issue 4/2017
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI: https://doi.org/10.1007/s11325-017-1510-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2017

Validation of NoSAS score for screening of sleep-disordered breathing in a multiethnic Asian population

Effect of rhythm control on sleep disordered breathing in patients with atrial fibrillation or flutter: a systematic review and meta-analysis

Can myofunctional therapy increase tongue tone and reduce symptoms in children with sleep-disordered breathing?

Drug-induced sedation endoscopy (DISE) classification systems: a systematic review and meta-analysis

Severity of desaturation events differs between hypopnea and obstructive apnea events and is modulated by their duration in obstructive sleep apnea

Renal function in patients with obstructive sleep apnea

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials